Key facts: Danaher strong cash; trims 2026 outlook; bio orders, $100M deferred

Danaher (DHR) Q2 2026: operating cash flow $1.534B, non‑GAAP free cash flow $1.265B. Life Sciences strongest quarter in years; Diagnostics boosted by respiratory testing components. 1
Danaher (DHR) beat quarterly results but cut Q3 core revenue outlook to 2%–3% and trimmed full-year core revenue guidance to 3%–4%; stock fell sharply on the guidance cut. 2
Danaher (DHR) saw mid-teens order growth in bioprocessing; revenue hit by ~$100M shipment timing deferral into next year; academic and government demand stabilized. 3
Danaher’s Leica Biosystems agreed to buy StatLab, a $250M consumables supplier (85%+ recurring revenue). Deal expected to close by end-2026 and be accretive to adjusted EPS in year one. 4

Danaher (DHR) reported strong Q2 2026 cash flow and beat earnings, driven by robust Life Sciences and Diagnostics performance. However, the company cut its Q3 core revenue outlook to 2%-3% and trimmed full-year guidance to 3%-4%, citing a $100M shipment timing deferral. Consequently, shares fell sharply. Additionally, Danaher's Leica Biosystems agreed to acquire StatLab for $250M, expected to close by end-2026.

Danaher (DHR) Q2 2026: operating cash flow $1.534B, non‑GAAP free cash flow $1.265B. Life Sciences strongest quarter in years; Diagnostics boosted by respiratory testing components. 1
Danaher (DHR) beat quarterly results but cut Q3 core revenue outlook to 2%–3% and trimmed full-year core revenue guidance to 3%–4%; stock fell sharply on the guidance cut. 2
Danaher (DHR) saw mid-teens order growth in bioprocessing; revenue hit by ~$100M shipment timing deferral into next year; academic and government demand stabilized. 3
Danaher’s Leica Biosystems agreed to buy StatLab, a $250M consumables supplier (85%+ recurring revenue). Deal expected to close by end-2026 and be accretive to adjusted EPS in year one. 4